Our proprietary antibody-drug conjugate (ADC) platform centers on using a novel linker to increase the likelihood of clinical success by delivering a potent, active drug while minimizing off-target activity.
Antibody-Drug Conjugate (ADC) Platform
Our ADCs combine three components to deliver an active drug, or payload, inside the tumor cell, as well as produce a bystander effect in the surrounding tumor microenvironment.
- Trop-2, which is found in many types of solid tumors (TRODELVY)
- CEACAM5, (IMMU-130)
- HLA-DR, (IMMU-140)
Our linker, called CL2A, is unique in 3 ways:
- It does not require an enzyme
- It can produce a bystander effect by delivering active drug both inside the tumor, as well as in the surrounding area
- It can support a high drug-to-antibody ratio. Our linker facilitates delivery of up to eight molecules of SN-38, the active drug, per antibody molecule inside the tumor cell and the tumor microenvironment. This ability to deliver so much active drug may explain why, in an animal model, our ADCs deliver more than 120 times the amount of SN-38 than when irinotecan, the parent drug, is administered intravenously.